What are the common etiologies of portal vein thrombosis in a patient without cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Common Etiologies of Portal Vein Thrombosis in Non-Cirrhotic Patients

In patients without cirrhosis, portal vein thrombosis is most commonly caused by myeloproliferative neoplasms, local inflammatory conditions (pancreatitis, inflammatory bowel disease, appendicitis, diverticulitis), and abdominal surgery (particularly bariatric surgery and splenectomy), with approximately 30% of patients also having an underlying systemic thrombophilic disorder. 1

Primary Etiologic Categories

The 2021 AASLD guidance clearly delineates that extrahepatic portal venous obstruction in non-cirrhotic patients is predominantly related to three major categories: 1

1. Myeloproliferative Neoplasms

  • This represents the single most common risk factor in non-cirrhotic PVT 2
  • Includes JAK2-positive disorders and CALR mutations
  • Should be the first consideration in your diagnostic workup

2. Local Inflammatory/Surgical Conditions

The following are important contributors to extrahepatic portal venous obstruction: 1

  • Surgical procedures: Bariatric surgery (particularly sleeve gastrectomy), splenectomy, hepatic or biliary surgery
  • Inflammatory abdominal conditions: Pancreatitis, inflammatory bowel disease, appendicitis, diverticulitis
  • Blunt abdominal trauma

Recent data confirms that extrahepatic inflammatory conditions are significantly more prevalent in non-cirrhotic versus cirrhotic PVT patients (found in 32% of non-cirrhotics vs. 0% in cirrhotics, p < 0.001) 3

3. Inherited and Acquired Thrombophilias

Approximately 30% of non-cirrhotic PVT patients have a concurrent systemic thrombophilic disorder 1

Among inherited thrombophilias, the G20210A prothrombin gene mutation is most prevalent in this population 1

Critical Clinical Approach

A detailed thrombophilia workup is warranted in most patients without cirrhosis who develop PVT - this contrasts sharply with cirrhotic patients where such testing rarely changes management 1

The AASLD guidance strongly recommends combined evaluation by an experienced hematologist and hepatologist for every non-cirrhotic patient who develops PVT 1

Additional Risk Factors to Consider

  • Malignancy: Extrahepatic solid-organ malignancy (found in 25.5% of cases in recent series) 4
  • Obesity: BMI ≥30 was present in 42.6% of non-cirrhotic PVT patients 4
  • Recent infection: Associated with 42.6% of cases and significantly linked to bowel ischemia (p = 0.016) 4
  • Prolonged immobilization 1

Important Clinical Pitfall

Approximately 24% of non-cirrhotic PVT cases have no identifiable risk factors despite thorough evaluation 1. This underscores the importance of maintaining a high index of suspicion even when obvious predisposing factors are absent.

The prevalence of non-cirrhotic PVT is rare (0.05% in autopsy studies), but this likely overestimates true prevalence due to post-mortem thrombosis 1. The prognosis is generally good and determined mainly by the underlying cause rather than portal hypertension complications 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.